Share Price and Basic Stock Data
Last Updated: December 24, 2025, 3:06 pm
| PEG Ratio | -1.36 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Dr Lalchandani Labs Ltd operates within the hospitals and medical services sector, a field that has seen significant fluctuations in demand and operational challenges in recent years. The company reported a market capitalization of ₹7.40 Cr and a current share price of ₹17.1. Revenue has been inconsistent, with sales peaking at ₹11.28 Cr in FY 2022 but subsequently dropping to ₹5.04 Cr in FY 2023. This decline reflects a broader trend in the sector, where post-pandemic recovery has proven uneven. In the trailing twelve months, revenues further declined to ₹4.81 Cr, suggesting ongoing challenges in stabilizing growth. The volatility in sales figures, particularly the drop from ₹9.78 Cr in FY 2021 to ₹5.04 Cr in FY 2023, raises questions about the company’s ability to regain momentum in a competitive environment.
Profitability and Efficiency Metrics
Profitability metrics for Dr Lalchandani Labs have shown a mixed performance. The operating profit margin (OPM) was reported at 21.89%, which appears strong compared to industry averages; however, the overall net profit has been erratic. The company recorded a net profit of ₹0.42 Cr for FY 2025, following a loss of ₹1.56 Cr in FY 2023. This inconsistency can be attributed to fluctuating operating expenses, which stood at ₹4.95 Cr in FY 2023 and declined to ₹4.59 Cr in FY 2024. The interest coverage ratio is notably robust at 10.90x, indicating that the company can comfortably cover its interest obligations. However, the return on equity (ROE) of 3.08% and return on capital employed (ROCE) of 2.81% suggest that while the company is generating profits, the returns are relatively low, signaling potential inefficiencies in capital utilization.
Balance Sheet Strength and Financial Ratios
The balance sheet of Dr Lalchandani Labs reflects a cautious financial stance, with total borrowings reported at ₹4.58 Cr against reserves of ₹5.82 Cr. This provides a solid cushion, suggesting that the company is not overly reliant on debt. The current and quick ratios are comfortably above 1, indicating a healthy liquidity position, which is crucial for operational stability in the medical services sector. However, the cash conversion cycle (CCC) of 556.91 days raises concerns, as it indicates a longer time frame to convert investments in inventory and receivables back into cash. This slow cycle could hinder operational efficiency, especially in a fast-paced industry where timely cash flow is essential. Additionally, the price-to-book value ratio of 0.44x suggests that the stock may be undervalued, which could attract potential investors looking for bargains.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Dr Lalchandani Labs has undergone significant changes, with promoter holdings declining from 60.78% in March 2020 to just 31.15% by September 2025. This shift indicates a potential dilution of control, which may raise concerns about strategic direction among retail investors. Conversely, public ownership has increased from 39.22% to 68.84% during the same period, reflecting growing investor interest. The number of shareholders has also surged, from 143 in March 2020 to 206 by September 2025. This growing base of retail investors could signal confidence in the company’s potential turnaround, despite the recent struggles. However, the reliance on public investors may also imply a need for the company to enhance transparency and communication to maintain trust and support.
Outlook, Risks, and Final Insight
Looking ahead, Dr Lalchandani Labs faces a precarious path. The recovery from recent financial setbacks is contingent upon improving operational efficiencies and stabilizing revenue streams. The volatility in sales, paired with a high cash conversion cycle, poses significant risks. Furthermore, the declining promoter stake could lead to questions about the company’s future direction and governance. On the upside, the strong interest coverage ratio and healthy liquidity position provide a buffer against immediate financial distress. Investors may wish to monitor future earnings reports closely for signs of recovery in profitability and operational performance. The company’s ability to navigate these challenges will ultimately determine its attractiveness as an investment in the evolving healthcare landscape. In this context, a cautious approach is warranted, weighing both the potential for recovery and the inherent risks of the current operational environment.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Dr Lalchandani Labs Ltd | 8.23 Cr. | 19.0 | 28.7/9.80 | 17.5 | 23.4 | 0.00 % | 2.81 % | 3.08 % | 10.0 |
| Asarfi Hospital Ltd | 366 Cr. | 186 | 221/72.9 | 26.0 | 45.2 | 0.00 % | 15.8 % | 14.1 % | 10.0 |
| Narayana Hrudayalaya Ltd | 38,335 Cr. | 1,874 | 2,372/1,257 | 45.1 | 199 | 0.24 % | 20.8 % | 24.2 % | 10.0 |
| Lotus Eye Hospital & Institute Ltd | 264 Cr. | 128 | 141/55.0 | 394 | 29.2 | 0.00 % | 2.99 % | 1.22 % | 10.0 |
| Industry Average | 12,988.33 Cr | 551.75 | 120.65 | 74.20 | 0.06% | 10.60% | 10.65% | 10.00 |
Quarterly Result
| Metric | Mar 2019 | Sep 2019 | Mar 2020 | Sep 2020 | Mar 2021 | Sep 2021 | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2.64 | 3.03 | 3.07 | 2.71 | 7.07 | 8.02 | 3.26 | 2.28 | 2.76 | 2.73 | 2.08 | 2.13 | 2.33 |
| Expenses | 1.95 | 2.30 | 2.53 | 2.14 | 5.40 | 6.07 | 2.81 | 2.46 | 2.50 | 2.38 | 1.04 | 1.59 | 1.82 |
| Operating Profit | 0.69 | 0.73 | 0.54 | 0.57 | 1.67 | 1.95 | 0.45 | -0.18 | 0.26 | 0.35 | 1.04 | 0.54 | 0.51 |
| OPM % | 26.14% | 24.09% | 17.59% | 21.03% | 23.62% | 24.31% | 13.80% | -7.89% | 9.42% | 12.82% | 50.00% | 25.35% | 21.89% |
| Other Income | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.24 | 0.00 | 0.00 |
| Interest | 0.05 | 0.09 | 0.09 | 0.05 | 0.30 | 0.24 | 0.33 | 0.48 | 0.51 | 0.11 | 0.28 | 0.05 | 0.03 |
| Depreciation | 0.20 | 0.21 | 0.22 | 0.23 | 0.29 | 0.28 | 0.30 | 0.33 | 0.34 | 0.33 | 0.29 | 0.28 | 0.28 |
| Profit before tax | 0.45 | 0.43 | 0.23 | 0.29 | 1.08 | 1.43 | -0.18 | -0.98 | -0.59 | -0.09 | 0.71 | 0.21 | 0.20 |
| Tax % | 26.67% | 0.00% | 82.61% | 24.14% | 27.78% | 25.17% | -22.22% | 0.00% | 0.00% | 0.00% | 0.00% | 23.81% | -35.00% |
| Net Profit | 0.34 | 0.43 | 0.04 | 0.23 | 0.79 | 1.07 | -0.13 | -0.97 | -0.59 | -0.09 | 0.71 | 0.15 | 0.27 |
| EPS in Rs | 0.78 | 0.99 | 0.09 | 0.53 | 1.82 | 2.47 | -0.30 | -2.24 | -1.36 | -0.21 | 1.64 | 0.35 | 0.62 |
Last Updated: May 31, 2025, 6:15 am
Below is a detailed analysis of the quarterly data for Dr Lalchandani Labs Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Sales, as of Mar 2025, the value is 2.33 Cr.. The value appears strong and on an upward trend. It has increased from 2.13 Cr. (Sep 2024) to 2.33 Cr., marking an increase of 0.20 Cr..
- For Expenses, as of Mar 2025, the value is 1.82 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.59 Cr. (Sep 2024) to 1.82 Cr., marking an increase of 0.23 Cr..
- For Operating Profit, as of Mar 2025, the value is 0.51 Cr.. The value appears to be declining and may need further review. It has decreased from 0.54 Cr. (Sep 2024) to 0.51 Cr., marking a decrease of 0.03 Cr..
- For OPM %, as of Mar 2025, the value is 21.89%. The value appears to be declining and may need further review. It has decreased from 25.35% (Sep 2024) to 21.89%, marking a decrease of 3.46%.
- For Other Income, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 0.00 Cr..
- For Interest, as of Mar 2025, the value is 0.03 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.05 Cr. (Sep 2024) to 0.03 Cr., marking a decrease of 0.02 Cr..
- For Depreciation, as of Mar 2025, the value is 0.28 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 0.28 Cr..
- For Profit before tax, as of Mar 2025, the value is 0.20 Cr.. The value appears to be declining and may need further review. It has decreased from 0.21 Cr. (Sep 2024) to 0.20 Cr., marking a decrease of 0.01 Cr..
- For Tax %, as of Mar 2025, the value is -35.00%. The value appears to be improving (decreasing) as expected. It has decreased from 23.81% (Sep 2024) to -35.00%, marking a decrease of 58.81%.
- For Net Profit, as of Mar 2025, the value is 0.27 Cr.. The value appears strong and on an upward trend. It has increased from 0.15 Cr. (Sep 2024) to 0.27 Cr., marking an increase of 0.12 Cr..
- For EPS in Rs, as of Mar 2025, the value is 0.62. The value appears strong and on an upward trend. It has increased from 0.35 (Sep 2024) to 0.62, marking an increase of 0.27.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 3:50 am
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 2.79 | 5.26 | 6.10 | 9.78 | 11.28 | 5.04 | 4.81 | 4.45 | 4.38 |
| Expenses | 2.17 | 4.06 | 4.84 | 7.54 | 8.81 | 4.95 | 4.59 | 3.52 | 3.61 |
| Operating Profit | 0.62 | 1.20 | 1.26 | 2.24 | 2.47 | 0.09 | 0.22 | 0.93 | 0.77 |
| OPM % | 22.22% | 22.81% | 20.66% | 22.90% | 21.90% | 1.79% | 4.57% | 20.90% | 17.58% |
| Other Income | 0.03 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 1.40 | 0.13 | 0.29 |
| Interest | 0.16 | 0.14 | 0.18 | 0.35 | 0.60 | 0.99 | 0.38 | 0.09 | 0.04 |
| Depreciation | 0.13 | 0.35 | 0.42 | 0.52 | 0.59 | 0.66 | 0.62 | 0.56 | 0.56 |
| Profit before tax | 0.36 | 0.72 | 0.66 | 1.37 | 1.28 | -1.56 | 0.62 | 0.41 | 0.46 |
| Tax % | 25.00% | 26.39% | 28.79% | 26.28% | 28.12% | 0.00% | 0.00% | -2.44% | |
| Net Profit | 0.26 | 0.53 | 0.47 | 1.01 | 0.93 | -1.56 | 0.62 | 0.42 | 0.47 |
| EPS in Rs | 0.89 | 1.22 | 1.08 | 2.33 | 2.15 | -3.60 | 1.43 | 0.97 | 1.08 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 103.85% | -11.32% | 114.89% | -7.92% | -267.74% | 139.74% | -32.26% |
| Change in YoY Net Profit Growth (%) | 0.00% | -115.17% | 126.21% | -122.81% | -259.82% | 407.49% | -172.00% |
Dr Lalchandani Labs Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 7 years from 2018-2019 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -6% |
| 3 Years: | -27% |
| TTM: | -7% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -2% |
| 3 Years: | -23% |
| TTM: | 155% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 19% |
| 3 Years: | 0% |
| 1 Year: | 21% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 0% |
| 3 Years: | -7% |
| Last Year: | 4% |
Last Updated: September 5, 2025, 3:16 pm
Balance Sheet
Last Updated: December 4, 2025, 2:46 am
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 2.93 | 4.33 | 4.33 | 4.33 | 4.33 | 4.33 | 4.33 | 4.33 | 4.33 |
| Reserves | 0.40 | 3.73 | 4.21 | 5.22 | 6.15 | 4.59 | 5.21 | 5.62 | 5.82 |
| Borrowings | 1.88 | 0.90 | 1.76 | 4.04 | 5.15 | 6.40 | 3.48 | 4.07 | 4.58 |
| Other Liabilities | 1.00 | 1.18 | 1.63 | 1.61 | 2.49 | 2.40 | 1.97 | 1.72 | 1.36 |
| Total Liabilities | 6.21 | 10.14 | 11.93 | 15.20 | 18.12 | 17.72 | 14.99 | 15.74 | 16.09 |
| Fixed Assets | 2.06 | 3.28 | 3.47 | 5.24 | 5.75 | 5.39 | 3.99 | 3.51 | 3.38 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.24 | 0.24 | 0.24 | 0.24 | 0.24 | 0.24 | 0.41 | 0.27 | 0.27 |
| Other Assets | 3.91 | 6.62 | 8.22 | 9.72 | 12.13 | 12.09 | 10.59 | 11.96 | 12.44 |
| Total Assets | 6.21 | 10.14 | 11.93 | 15.20 | 18.12 | 17.72 | 14.99 | 15.74 | 16.09 |
Below is a detailed analysis of the balance sheet data for Dr Lalchandani Labs Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 4.33 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 4.33 Cr..
- For Reserves, as of Sep 2025, the value is 5.82 Cr.. The value appears strong and on an upward trend. It has increased from 5.62 Cr. (Mar 2025) to 5.82 Cr., marking an increase of 0.20 Cr..
- For Borrowings, as of Sep 2025, the value is 4.58 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 4.07 Cr. (Mar 2025) to 4.58 Cr., marking an increase of 0.51 Cr..
- For Other Liabilities, as of Sep 2025, the value is 1.36 Cr.. The value appears to be improving (decreasing). It has decreased from 1.72 Cr. (Mar 2025) to 1.36 Cr., marking a decrease of 0.36 Cr..
- For Total Liabilities, as of Sep 2025, the value is 16.09 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 15.74 Cr. (Mar 2025) to 16.09 Cr., marking an increase of 0.35 Cr..
- For Fixed Assets, as of Sep 2025, the value is 3.38 Cr.. The value appears to be declining and may need further review. It has decreased from 3.51 Cr. (Mar 2025) to 3.38 Cr., marking a decrease of 0.13 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 0.27 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.27 Cr..
- For Other Assets, as of Sep 2025, the value is 12.44 Cr.. The value appears strong and on an upward trend. It has increased from 11.96 Cr. (Mar 2025) to 12.44 Cr., marking an increase of 0.48 Cr..
- For Total Assets, as of Sep 2025, the value is 16.09 Cr.. The value appears strong and on an upward trend. It has increased from 15.74 Cr. (Mar 2025) to 16.09 Cr., marking an increase of 0.35 Cr..
Notably, the Reserves (5.82 Cr.) exceed the Borrowings (4.58 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -1.26 | 0.30 | -0.50 | -1.80 | -2.68 | -6.31 | -3.26 | -3.14 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 149.14 | 126.99 | 199.25 | 148.54 | 136.55 | 359.93 | 356.65 | 431.44 |
| Inventory Days | 167.03 | 233.36 | 158.70 | 68.75 | 191.07 | 458.51 | 255.15 | 490.47 |
| Days Payable | 426.86 | 406.89 | 355.48 | 97.06 | 175.15 | 404.21 | 217.94 | 365.00 |
| Cash Conversion Cycle | -110.69 | -46.54 | 2.47 | 120.23 | 152.47 | 414.23 | 393.86 | 556.91 |
| Working Capital Days | 162.22 | 167.23 | 206.43 | 104.50 | 77.98 | 188.29 | 163.91 | 156.66 |
| ROCE % | 12.14% | 8.72% | 14.40% | 12.87% | -3.68% | -2.68% | 2.81% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 0.96 | 1.43 | -3.61 | 2.15 | 2.33 |
| Diluted EPS (Rs.) | 0.96 | 1.43 | -3.61 | 2.15 | 2.33 |
| Cash EPS (Rs.) | 2.27 | 2.87 | -2.08 | 3.51 | 3.52 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 22.94 | 21.98 | 20.56 | 24.16 | 22.01 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 22.98 | 22.02 | 20.59 | 24.20 | 22.04 |
| Revenue From Operations / Share (Rs.) | 10.28 | 11.10 | 11.63 | 26.03 | 22.57 |
| PBDIT / Share (Rs.) | 2.15 | 1.00 | 0.20 | 5.55 | 5.12 |
| PBIT / Share (Rs.) | 0.84 | -0.43 | -1.33 | 4.20 | 3.93 |
| PBT / Share (Rs.) | 0.92 | 1.43 | -3.61 | 2.97 | 3.18 |
| Net Profit / Share (Rs.) | 0.96 | 1.43 | -3.61 | 2.15 | 2.33 |
| PBDIT Margin (%) | 20.89 | 9.04 | 1.75 | 21.33 | 22.68 |
| PBIT Margin (%) | 8.22 | -3.93 | -11.40 | 16.12 | 17.41 |
| PBT Margin (%) | 9.03 | 12.83 | -31.00 | 11.41 | 14.08 |
| Net Profit Margin (%) | 9.36 | 12.83 | -31.00 | 8.27 | 10.34 |
| Return on Networth / Equity (%) | 4.19 | 6.48 | -17.54 | 8.91 | 10.60 |
| Return on Capital Employeed (%) | 3.63 | -1.89 | -4.63 | 13.71 | 13.81 |
| Return On Assets (%) | 2.64 | 4.11 | -8.82 | 5.14 | 6.65 |
| Long Term Debt / Equity (X) | 0.00 | 0.02 | 0.37 | 0.25 | 0.27 |
| Total Debt / Equity (X) | 0.40 | 0.35 | 0.52 | 0.38 | 0.35 |
| Asset Turnover Ratio (%) | 0.28 | 0.29 | 0.28 | 0.67 | 0.72 |
| Current Ratio (X) | 1.92 | 1.88 | 2.07 | 2.22 | 2.98 |
| Quick Ratio (X) | 1.69 | 1.60 | 1.78 | 1.90 | 2.75 |
| Inventory Turnover Ratio (X) | 3.26 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 10.90 | 1.13 | 0.08 | 4.52 | 6.81 |
| Interest Coverage Ratio (Post Tax) (X) | 4.46 | -0.49 | -0.58 | 2.75 | 4.10 |
| Enterprise Value (Cr.) | 5.20 | 7.92 | 13.89 | 14.81 | 6.53 |
| EV / Net Operating Revenue (X) | 1.17 | 1.65 | 2.76 | 1.31 | 0.66 |
| EV / EBITDA (X) | 5.58 | 18.19 | 157.32 | 6.15 | 2.94 |
| MarketCap / Net Operating Revenue (X) | 0.99 | 1.42 | 2.44 | 1.27 | 0.61 |
| Price / BV (X) | 0.44 | 0.71 | 1.38 | 1.37 | 0.63 |
| Price / Net Operating Revenue (X) | 0.99 | 1.42 | 2.44 | 1.27 | 0.61 |
| EarningsYield | 0.09 | 0.09 | -0.12 | 0.06 | 0.16 |
After reviewing the key financial ratios for Dr Lalchandani Labs Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.96. This value is below the healthy minimum of 5. It has decreased from 1.43 (Mar 24) to 0.96, marking a decrease of 0.47.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.96. This value is below the healthy minimum of 5. It has decreased from 1.43 (Mar 24) to 0.96, marking a decrease of 0.47.
- For Cash EPS (Rs.), as of Mar 25, the value is 2.27. This value is below the healthy minimum of 3. It has decreased from 2.87 (Mar 24) to 2.27, marking a decrease of 0.60.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 22.94. It has increased from 21.98 (Mar 24) to 22.94, marking an increase of 0.96.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 22.98. It has increased from 22.02 (Mar 24) to 22.98, marking an increase of 0.96.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 10.28. It has decreased from 11.10 (Mar 24) to 10.28, marking a decrease of 0.82.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 2.15. This value is within the healthy range. It has increased from 1.00 (Mar 24) to 2.15, marking an increase of 1.15.
- For PBIT / Share (Rs.), as of Mar 25, the value is 0.84. This value is within the healthy range. It has increased from -0.43 (Mar 24) to 0.84, marking an increase of 1.27.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.92. This value is within the healthy range. It has decreased from 1.43 (Mar 24) to 0.92, marking a decrease of 0.51.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.96. This value is below the healthy minimum of 2. It has decreased from 1.43 (Mar 24) to 0.96, marking a decrease of 0.47.
- For PBDIT Margin (%), as of Mar 25, the value is 20.89. This value is within the healthy range. It has increased from 9.04 (Mar 24) to 20.89, marking an increase of 11.85.
- For PBIT Margin (%), as of Mar 25, the value is 8.22. This value is below the healthy minimum of 10. It has increased from -3.93 (Mar 24) to 8.22, marking an increase of 12.15.
- For PBT Margin (%), as of Mar 25, the value is 9.03. This value is below the healthy minimum of 10. It has decreased from 12.83 (Mar 24) to 9.03, marking a decrease of 3.80.
- For Net Profit Margin (%), as of Mar 25, the value is 9.36. This value is within the healthy range. It has decreased from 12.83 (Mar 24) to 9.36, marking a decrease of 3.47.
- For Return on Networth / Equity (%), as of Mar 25, the value is 4.19. This value is below the healthy minimum of 15. It has decreased from 6.48 (Mar 24) to 4.19, marking a decrease of 2.29.
- For Return on Capital Employeed (%), as of Mar 25, the value is 3.63. This value is below the healthy minimum of 10. It has increased from -1.89 (Mar 24) to 3.63, marking an increase of 5.52.
- For Return On Assets (%), as of Mar 25, the value is 2.64. This value is below the healthy minimum of 5. It has decreased from 4.11 (Mar 24) to 2.64, marking a decrease of 1.47.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. It has decreased from 0.02 (Mar 24) to 0.00, marking a decrease of 0.02.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.40. This value is within the healthy range. It has increased from 0.35 (Mar 24) to 0.40, marking an increase of 0.05.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.28. It has decreased from 0.29 (Mar 24) to 0.28, marking a decrease of 0.01.
- For Current Ratio (X), as of Mar 25, the value is 1.92. This value is within the healthy range. It has increased from 1.88 (Mar 24) to 1.92, marking an increase of 0.04.
- For Quick Ratio (X), as of Mar 25, the value is 1.69. This value is within the healthy range. It has increased from 1.60 (Mar 24) to 1.69, marking an increase of 0.09.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.26. This value is below the healthy minimum of 4. It has increased from 0.00 (Mar 24) to 3.26, marking an increase of 3.26.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 10.90. This value is within the healthy range. It has increased from 1.13 (Mar 24) to 10.90, marking an increase of 9.77.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 4.46. This value is within the healthy range. It has increased from -0.49 (Mar 24) to 4.46, marking an increase of 4.95.
- For Enterprise Value (Cr.), as of Mar 25, the value is 5.20. It has decreased from 7.92 (Mar 24) to 5.20, marking a decrease of 2.72.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.17. This value is within the healthy range. It has decreased from 1.65 (Mar 24) to 1.17, marking a decrease of 0.48.
- For EV / EBITDA (X), as of Mar 25, the value is 5.58. This value is within the healthy range. It has decreased from 18.19 (Mar 24) to 5.58, marking a decrease of 12.61.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.99. This value is below the healthy minimum of 1. It has decreased from 1.42 (Mar 24) to 0.99, marking a decrease of 0.43.
- For Price / BV (X), as of Mar 25, the value is 0.44. This value is below the healthy minimum of 1. It has decreased from 0.71 (Mar 24) to 0.44, marking a decrease of 0.27.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.99. This value is below the healthy minimum of 1. It has decreased from 1.42 (Mar 24) to 0.99, marking a decrease of 0.43.
- For EarningsYield, as of Mar 25, the value is 0.09. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.09.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Dr Lalchandani Labs Ltd:
- Net Profit Margin: 9.36%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 3.63% (Industry Average ROCE: 10.6%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 4.19% (Industry Average ROE: 10.65%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 4.46
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.69
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 17.5 (Industry average Stock P/E: 120.65)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.4
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 9.36%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Hospitals & Medical Services | M-20, Basement, Greater Kailash, New Delhi Delhi 110048 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Dr. Arjan Lal Chandani | Chairman & Managing Director |
| Mr. Mohit Lal Chandani | WholeTime Director & CEO |
| Mrs. Anchal Gupta | Executive Director & CFO |
| Mrs. Swati Chandra | Non Executive Director |
| Mr. Rajiv Handa | Independent Director |
| Mr. Mohan Lal Gandhi | Independent Director |
FAQ
What is the intrinsic value of Dr Lalchandani Labs Ltd?
Dr Lalchandani Labs Ltd's intrinsic value (as of 24 December 2025) is 10.29 which is 45.84% lower the current market price of 19.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 8.23 Cr. market cap, FY2025-2026 high/low of 28.7/9.80, reserves of ₹5.82 Cr, and liabilities of 16.09 Cr.
What is the Market Cap of Dr Lalchandani Labs Ltd?
The Market Cap of Dr Lalchandani Labs Ltd is 8.23 Cr..
What is the current Stock Price of Dr Lalchandani Labs Ltd as on 24 December 2025?
The current stock price of Dr Lalchandani Labs Ltd as on 24 December 2025 is 19.0.
What is the High / Low of Dr Lalchandani Labs Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Dr Lalchandani Labs Ltd stocks is 28.7/9.80.
What is the Stock P/E of Dr Lalchandani Labs Ltd?
The Stock P/E of Dr Lalchandani Labs Ltd is 17.5.
What is the Book Value of Dr Lalchandani Labs Ltd?
The Book Value of Dr Lalchandani Labs Ltd is 23.4.
What is the Dividend Yield of Dr Lalchandani Labs Ltd?
The Dividend Yield of Dr Lalchandani Labs Ltd is 0.00 %.
What is the ROCE of Dr Lalchandani Labs Ltd?
The ROCE of Dr Lalchandani Labs Ltd is 2.81 %.
What is the ROE of Dr Lalchandani Labs Ltd?
The ROE of Dr Lalchandani Labs Ltd is 3.08 %.
What is the Face Value of Dr Lalchandani Labs Ltd?
The Face Value of Dr Lalchandani Labs Ltd is 10.0.